At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Jan 2007 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 15 Apr 1998 Preclinical development for Thrombosis in USA (Unknown route)